Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) - PubMed (original) (raw)
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
R Duchmann et al. Clin Exp Immunol. 1995 Dec.
Abstract
Hyporesponsiveness to a universe of bacterial and dietary antigens from the gut lumen is a hallmark of the intestinal immune system. Since hyperresponsiveness against these antigens might be associated with inflammation, we studied the immune response to the indigenous intestinal microflora in peripheral blood, inflamed and non-inflamed human intestine. Lamina propria monocuclear cells (LPMC) isolated from inflamed intestine but not peripheral blood mononuclear cells (PBMC) of IBD patients with active inflammatory disease strongly proliferated after co-culture with sonicates of bacteria from autologous intestine (BsA). Proliferation was inhibitable by anti-MHC class II MoAb, suggesting that it was driven by antigen. LPMC from adjacent non-inflamed intestinal areas of the same IBD patients and PBMC or LPMC isolated from non-inflamed intestine of controls and patients with IBD in remission, in contrast, did not proliferate. PBMC or LPMC which had been tolerant to bacteria from autologous intestine, however, strongly proliferated after co-culture with bacterial sonicates from heterologous intestine (BsH). This proliferation was associated with an expansion of CD8+ T cells, increased expression of activation markers on both CD4+ and CD8+ lymphocyte subsets, and production of IL-12, interferon-gamma (IFN-gamma), and IL-10 protein. These results show that tolerance selectively exists to intestinal flora from autologous but not heterologous intestine, and that tolerance is broken in intestinal inflammation. This may be an important mechanism for the perpetuation of chronic IBD.
Comment in
- Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD).
MacDonald TT. MacDonald TT. Clin Exp Immunol. 1995 Dec;102(3):445-7. doi: 10.1111/j.1365-2249.1995.tb03835.x. Clin Exp Immunol. 1995. PMID: 8536355 Free PMC article. No abstract available.
Similar articles
- Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Duchmann R, et al. Eur J Immunol. 1996 Apr;26(4):934-8. doi: 10.1002/eji.1830260432. Eur J Immunol. 1996. PMID: 8625991 - Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease.
Sato T, Kanai T, Watanabe M, Sakuraba A, Okamoto S, Nakai T, Okazawa A, Inoue N, Totsuka T, Yamazaki M, Kroczek RA, Fukushima T, Ishii H, Hibi T. Sato T, et al. Gastroenterology. 2004 Mar;126(3):829-39. doi: 10.1053/j.gastro.2003.12.011. Gastroenterology. 2004. PMID: 14988837 - Bacteria-specific T-cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease.
Duchmann R, Märker-Hermann E, Meyer zum Büschenfelde KH. Duchmann R, et al. Scand J Immunol. 1996 Jul;44(1):71-9. doi: 10.1046/j.1365-3083.1996.d01-273.x. Scand J Immunol. 1996. PMID: 8693294 - The pathogenic role of intestinal flora in IBD and colon cancer.
Rescigno M. Rescigno M. Curr Drug Targets. 2008 May;9(5):395-403. doi: 10.2174/138945008784221125. Curr Drug Targets. 2008. PMID: 18473768 Review. - Gut biofilm forming bacteria in inflammatory bowel disease.
Srivastava A, Gupta J, Kumar S, Kumar A. Srivastava A, et al. Microb Pathog. 2017 Nov;112:5-14. doi: 10.1016/j.micpath.2017.09.041. Epub 2017 Sep 20. Microb Pathog. 2017. PMID: 28942174 Review.
Cited by
- Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy.
Kong C, Yang M, Yue N, Zhang Y, Tian C, Wei D, Shi R, Yao J, Wang L, Li D. Kong C, et al. J Inflamm Res. 2024 Aug 14;17:5389-5413. doi: 10.2147/JIR.S470520. eCollection 2024. J Inflamm Res. 2024. PMID: 39161679 Free PMC article. Review. - Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer.
Kumar A, Vaiphei KK, Singh N, Datta Chigurupati SP, Paliwal SR, Paliwal R, Gulbake A. Kumar A, et al. Nanomedicine (Lond). 2024 Jun 20;19(15):1347-1368. doi: 10.1080/17435889.2024.2350356. Epub 2024 Jun 10. Nanomedicine (Lond). 2024. PMID: 39105753 Review. - Crohn's disease treatment and memory T-cell subset changes: insights from a case series.
Chen ZH, Tang YY, Sheng SY, Lu CG, Xu KW, Chen GJ, Wang YF, Gu Y, Song XM, Hong H. Chen ZH, et al. Transl Gastroenterol Hepatol. 2024 Feb 4;9:18. doi: 10.21037/tgh-23-21. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 38716221 Free PMC article. - The Impact of Phenotype of Inflammatory Bowel Diseases, Inflammation Activity and Therapy on Mucosal Mature Cd83+ Dendritic Cell.
Rošić Despalatović B, Babić M, Bratanić A, Tonkić A, Ardalić Ž, Vilović K. Rošić Despalatović B, et al. J Clin Med. 2024 Apr 3;13(7):2070. doi: 10.3390/jcm13072070. J Clin Med. 2024. PMID: 38610835 Free PMC article. - Gut Microbiome-Related Anti-Inflammatory Effects of Aryl Hydrocarbon Receptor Activation on Inflammatory Bowel Disease.
Moutusy SI, Ohsako S. Moutusy SI, et al. Int J Mol Sci. 2024 Mar 16;25(6):3372. doi: 10.3390/ijms25063372. Int J Mol Sci. 2024. PMID: 38542367 Free PMC article. Review.
References
- Cell. 1990 Dec 21;63(6):1249-56 - PubMed
- J Immunol. 1993 Jan 15;150(2):353-60 - PubMed
- Gastroenterology. 1993 Nov;105(5):1421-30 - PubMed
- Immunol Today. 1992 Jan;13(1):11-6 - PubMed
- Scand J Gastroenterol. 1988 Nov;23(9):1125-31 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials